Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04791566
Other study ID # H-20038432
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 1, 2021
Est. completion date December 9, 2022

Study information

Verified date December 2022
Source Copenhagen University Hospital, Hvidovre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this trial is to evaluate the effect of high-dose glucocorticoid on inflammatory response and recovery after emergency laparotomy in participants with intestinal obstruction and perforated viscus. Primary outcome is the reduction of C-reactive protein on postoperative day 1. Secondary outcomes are organ specific complications in the post anaesthesia phase, endothel and inflammatory markers, fluid status, preload dependency, pain, lung function, nausea and mobilization during the first 5 days after surgery, . The investigators hypothesize, that a preoperative single high dose of glucocorticoid reduces systemic inflammatory response after emergency laparotomy.


Description:

Surgical trauma and accompanying inflammation results in increased capillary permeability leading to tissue edema. Since the vascular endothelium contributes to homeostasis, endothelial damage may increase the risk of cardiovascular and hemodynamic complications. Pre-operative high-dose glucocorticoids provide reduction in the inflammatory response after surgery, effective pain relief in several major surgical procedures, as well as reducing fatigue, impairing endothelial dysfunction, potentially amend fluid extravasation, edema and dyscoagulation and vasodilation. However, glucocorticoids have not been assessed in patients with peritonitis or intestinal obstruction, specifically, the impact on pain, fluid dynamics, respiratory as well as endothelial function and mobilization in both obstruction and perforation. In this study, patients will be randomized to either high dose dexamethason (1 mg /kg) or placebo (0,9% NaCl), administered as a single dose preoperatively. The investigatoris hypothesize that a preoperative single high dose of glucocorticoid reduces systemic inflammatory response after emergency laparotomy.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date December 9, 2022
Est. primary completion date October 9, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults (18 years or over) undergoing emergency laparotomy (laparotomy or laparoscopy) for following abdominal pathology: 1. Primary perforated viscus (perforated ulcer, small intestine or colon) 2. Primary intestinal obstruction ( small intestine or colon) 2. Provided verbal and written informed consent 3. Must speak and understand the Danish language Exclusion Criteria: 1. Appendectomies, cholecystectomies, negative diagnostic laparoscopies/laparotomies, herniotomies without bowel resections, sub-acute internal hernias after gastric bypass surgery, sub-acute surgery for inflammatory bowel diseases. 2. Emergency re-operations after elective surgery owing to paralytic/obstructive ileus, perforated viscus, anastomotic leakage 3. Reoperation owing to fascial separation with no other abdominal pathology identified and sub-acute colorectal cancer-surgery will be excluded from the cohort. Sub-acute surgery is defined as surgery planned within 48 hours. 4. Intestinal Ischemia 5. intraabdominal bleeding 6. Traumas, gynecological, urogenital and other vascular pathology, pregnant participants. 7. Dementia and/or cognitive dysfunction (diagnosed). 8. Participants not oriented in time, place and person 9. Insuline treatment for diabetes mellitus type I and II 10. Current treatment with systemic glucocorticoids or immune suppressive treatment ( apart from inhalation steroids) 11. Allergies to trial medicine -

Study Design


Intervention

Drug:
Dexamethasone 1 mg/kg
Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
Physiologic saline
100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia

Locations

Country Name City State
Denmark Mirjana Cihoric Hvidovre

Sponsors (1)

Lead Sponsor Collaborator
Mirjana Cihoric

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other changes in postoperative inflammatory responses (IL-6, TNF alfa) Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Change in plasma Syndecain-1sE-Selectin (CD62E) Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Change in plasma soluble thrombomodulin (sTM)(CD141) Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Change in plasma sE-Selectin (CD62E) Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Change in vascular endothelial growth factor (VEGF) 0 to 1 point: Not high risk; 2 to 3 points: High risk Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other quick Sequential Organ Failure Assessment score, qSOFA Assessed once preoperatively and 4 times daily during the first 5 postoperative days
Other Preload dependency via stroke volume(SV) guided resuscitation Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Fluid distribution, full body water via bioelectrical impedance vector analysis Preoperatively, 6 hours postoperatively, as well as postoperative day 1,3 and 5
Other Peak flow measurements Once a day on postoperative day 1,3 and 5
Other Postoperative need for antiemetic and analgesic beyond standard course Once a day during the the first 5 postoperative days
Other Mobilization, The Cumulated Ambulation Score (CAS) The CAS describes the patient's independence with regard to three activities (getting in and out of bed, sit-to-stand-to-sit from a chair, and walking). Each activity is assessed on a three-point ordinal scale from 0-2 (0 = Not able to, despite human assistance and verbal cueing, 1 = Able to, with human assistance and/or verbal cueing from one or more persons, 2 = Able to safely, without human assistance or verbal cueing, use of a walking aid allowed) resulting in a total daily CAS score ranging from zero to six Once a day on postoperative day 1,3 and 5
Other Postoperative delirium via Confusion Assessment method scale 1.a: Acute onset
1b: Fluctuating course, 2: inattention 3: disorganized thinking 4: altered level of conciosness At least one criterion must be met for a positive result
Once a day during the the first 5 postoperative days
Other Postoperative resting pain measured according to Numeric Rating Scale (NRS) 0-10 where 0 is no pain and 10 is the worst pain imaginable 6 hours after surgery as well as once a day one postoperative day 1,3 and 5
Other Postoperative pain during mobilization, measured according to Numeric Rating Scale (NRS) 0-10 where 0 is no pain and 10 is the worst pain imaginable 6 hours after surgery as well as once one postoperative day 1,3 and 5
Other 30-day postoperative mortality 30 days
Other 90-day postoperative mortality 90 days
Other 30-day postoperative complications 30 days
Other Length of ICU stay 30 days
Other Overall hospital stay 30 days
Other Plasma NO-bioavailability (L-arginine, asymmetric dimethylarginine) preoperatively, 6 hours after surgery as well as once one postoperative day 1,3 and 5
Primary plasma C-reactive protein 24* hours (*+/- 6 hours) after surgery.
Secondary changes in plasma C-reactive protein Preoperatively, 6 hours postoperatively, as well as postoperative day 3 and 5
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3